Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151,800 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations.
Liao J, Liu C, Long Q, Wu X, Wang H, Yu H, Sun S, Zhang Y, Lin Y, Zhao X, Wang J. Liao J, et al. Among authors: wang h, wang j. Front Oncol. 2021 Sep 29;11:752545. doi: 10.3389/fonc.2021.752545. eCollection 2021. Front Oncol. 2021. PMID: 34660317 Free PMC article.
Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study.
Qin S, Yu H, Wu X, Luo Z, Wang H, Sun S, Huang M, Jin J, Tao Z, Qiao J, Feng Y, Wang J, Chang J. Qin S, et al. Among authors: wang h, wang j. Chin J Cancer Res. 2019 Apr;31(2):339-348. doi: 10.21147/j.issn.1000-9604.2019.02.08. Chin J Cancer Res. 2019. PMID: 31156304 Free PMC article.
151,800 results
You have reached the last available page of results. Please see the User Guide for more information.